Jan-Erik Frödin

Publications
CV
Public outreach and news

Articles

Article: PLOS ONE. 2024;19(3):e0294018

Efficacy of hyperthermic intraperitoneal chemotherapy in colorectal cancer: A phase I and III open label randomized controlled registry-based clinical trial protocol.

Ghanipour L; Jansson Palmer G; Nilsson PJ; Nordenvall C; Frödin J-E; Bexe Lindskog E; Asplund D; Swartling T; Graf W; Birgisson H; Syk I; Verwaal V; Brändstedt J; Cashin PH
Article: ESMO OPEN. 2023;8(2):101158

The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trial.

Dijkstra EA; Zwart WH; Nilsson PJ; Putter H; Roodvoets AGH; Meershoek-Klein Kranenbarg E; Frödin JE; Nygren P; Østergaard L; Kersten C; Verbiené I; Cervantes A; Hendriks MP; Capdevila J; Edhemovic I; van de Velde CJH; Marijnen CAM; van Etten B; Hospers GAP; Glimelius B; collaborative investigators
Article: CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY. 2023;39:100562

Preoperative short-course radiation therapy with PROtons compared to photons in high-risk RECTal cancer (PRORECT): Initial dosimetric experience.

Pedone C; Sorcini B; Staff C; Färlin J; Fokstuen T; Frödin J-E; Nilsson PJ; Martling A; Valdman A
Article: CANCERS. 2022;14(24):6238

Associations between Response to Commonly Used Neo-Adjuvant Schedules in Rectal Cancer and Routinely Collected Clinical and Imaging Parameters.

Karimi M; Osterlund P; Hammarström K; Imam I; Frodin J-E; Glimelius B
Article: ESMO OPEN. 2022;7(3):100427

Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.

Osterlund P; Kinos S; Pfeiffer P; Salminen T; Kwakman JJM; Frödin J-E; Shah CH; Sorbye H; Ristamäki R; Halonen P; Soveri LM; Heervä E; Ålgars A; Bärlund M; Hagman H; McDermott R; O'Reilly M; Röckert R; Liposits G; Kallio R; Flygare P; Teske AJ; van Werkhoven E; Punt CJA; Glimelius B
Article: BJS OPEN. 2021;5(6):zrab137

Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial.

Erlandsson J; Fuentes S; Radu C; Frödin J-E; Johansson H; Brandberg Y; Holm T; Glimelius B; Martling A
Article: JOURNAL OF PATIENT-REPORTED OUTCOMES. 2021;5(1):58

Quality of life assessments in clinical practice using either the EORTC-QLQ-C30 or the SEIOQL-DW: a randomized study.

Kettis Å; Fagerlind H; Frödin J-E; Glimelius B; Ring L
Article: EJSO. 2018;44(7):983-990

Quality of life and cost effectiveness in a randomized trial of patients with colorectal cancer and peritoneal metastases.

Cashin PH; Mahteme H; Syk I; Frödin JE; Glimelius B; Graf W
Article: ANNALS OF SURGERY. 2018;267(2):326-331

Risk of Acute Testicular Failure After Preoperative Radiotherapy for Rectal Cancer: A Prospective Cohort Study.

Buchli C; Martling A; Abani MA; Frödin J-E; Bottai M; Lax I; Arver S; Holm T
Article: HEREDITARY CANCER IN CLINICAL PRACTICE. 2018;16:16

A retrospective study of extracolonic, non-endometrial cancer in Swedish Lynch syndrome families.

Karimi M; von Salomé J; Aravidis C; Silander G; Askmalm MS; Henriksson I; Gebre-Medhin S; Frödin J-E; Björck E; Lagerstedt-Robinson K; Lindblom A; Tham E
Article: INTERNATIONAL JOURNAL OF CANCER. 2017;140(2):431-439

Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.

Sclafani F; Kim TY; Cunningham D; Kim TW; Tabernero J; Schmoll HJ; Roh JK; Kim SY; Park YS; Guren TK; Hawkes E; Clarke SJ; Ferry D; Frodin J-E; Ayers M; Nebozhyn M; Peckitt C; Loboda A; Watkins DJ
Article: PANCREATOLOGY. 2016;16(4):640-645

A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer.

Löhr J-M; Karimi M; Omazic B; Kartalis N; Verbeke CS; Berkenstam A; Frödin J-E
Article: ACTA ONCOLOGICA. 2016;55(4):496-501

Assessment of testicular dose during preoperative radiotherapy for rectal cancer.

Buchli C; Al Abani M; Ahlberg M; Holm T; Fokstuen T; Bottai M; Frödin J-E; Lax I; Martling A
Article: ACTA ONCOLOGICA. 2016;55(2):140-148

A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial.

Ekman S; Harmenberg J; Frödin J-E; Bergström S; Wassberg C; Eksborg S; Larsson O; Axelson M; Jerling M; Abrahmsen L; Hedlund Å; Alvfors C; Ståhl B; Bergqvist M
Article: EUROPEAN JOURNAL OF CANCER. 2016;53:155-162

Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.

Cashin PH; Mahteme H; Spång N; Syk I; Frödin JE; Torkzad M; Glimelius B; Graf W
Article: ANNALS OF ONCOLOGY. 2016;27(1):140-147

A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial.

Hagman H; Frödin J-E; Berglund Å; Sundberg J; Vestermark LW; Albertsson M; Fernebro E; Johnsson A
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2015;107(12):djv258

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.

Sclafani F; Kim TY; Cunningham D; Kim TW; Tabernero J; Schmoll HJ; Roh JK; Kim SY; Park YS; Guren TK; Hawkes E; Clarke SJ; Ferry D; Frödin J-E; Ayers M; Nebozhyn M; Peckitt C; Loboda A; Mauro DJ; Watkins DJ
Article: ACTA ONCOLOGICA. 2015;54(7):1056-1062

Why is intravenous chemotherapy cancelled and how often. Could it be prevented? A prospective analysis of all planned and given intravenous anti-tumor treatments at the Department of Oncology, Karolinska University Hospital, Stockholm during one month.

Fuentes S; Frödin J-E
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2014;45(3):1293-1303

Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients.

Staff C; Mozaffari F; Frödin J-E; Mellstedt H; Liljefors M
Article: ANNALS OF ONCOLOGY. 2013;24(9):2335-2341

A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.

Johnsson A; Hagman H; Frödin J-E; Berglund A; Keldsen N; Fernebro E; Sundberg J; De Pont Christensen R; Garm Spindler K-L; Bergström D; Jakobsen A
Article: JOURNAL OF CLINICAL IMMUNOLOGY. 2012;32(4):855-865

Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein.

Staff C; Magnusson CGM; Hojjat-Farsangi M; Mosolits S; Liljefors M; Frödin J-E; Wahrén B; Mellstedt H; Ullenhag GJ
Article: ACTA ONCOLOGICA. 2011;50(3):441-447

Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma.

Ekman S; Frödin J-E; Harmenberg J; Bergman A; Hedlund A; Dahg P; Alvfors C; Ståhl B; Bergström S; Bergqvist M
Article: ANNALS OF ONCOLOGY. 2010;21(5):1020-1026

A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer.

Glimelius B; Lahn M; Gawande S; Cleverly A; Darstein C; Musib L; Liu Y; Spindler KL; Frödin J-E; Berglund A; Byström P; Qvortrup C; Jakobsen A; Pfeiffer P
Article: MEDICAL ONCOLOGY. 2010;27(1):65-72

An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer.

Berglund A; Byström P; Johansson B; Nygren P; Frödin J-E; Pedersen D; Letocha H; Glimelius B
Article: ANNALS OF ONCOLOGY. 2009;20(6):1057-1061

Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer.

Byström P; Berglund A; Garske U; Jacobsson H; Sundin A; Nygren P; Frödin J-E; Glimelius B
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2008;57(3):379-388

Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity.

Liljefors M; Nilsson B; Mellstedt H; Frödin J-E
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2007;56(7):973-984

A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients.

Hanson MGV; Ozenci V; Carlsten MCV; Glimelius BL; Frödin J-EA; Masucci G; Malmberg K-J; Kiessling RVR
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2005;54(6):557-570

T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody.

Mosolits S; Markovic K; Fagerberg J; Frödin J-E; Rezvany M-R; Kiaii S; Mellstedt H; Jeddi-Tehrani M
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2005;26(6):1581-1589

Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.

Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin J-E
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2004;25(3):703-711

Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.

Liljefors M; Ragnhammar P; Nilsson B; Ullenhag G; Mellstedt H; Frödin J-E
Article: CLINICAL CANCER RESEARCH. 2004;10(16):5391-5402

Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients.

Mosolits S; Markovic K; Frödin J-E; Virving L; Magnusson CGM; Steinitz M; Fagerberg J; Mellstedt H
Article: ANTICANCER RESEARCH. 2004;24(4):2375-2383

Spectrum of cytokeratin-positive cells in the bone marrows of colorectal carcinoma patients.

Shetye JD; Liljefors ML; Emdin SO; Frödin J-E; Strigård K; Mellstedt HT; Porwit A
Article: CLINICAL CANCER RESEARCH. 2004;10(10):3273-3281

Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor.

Ullenhag GJ; Frödin J-E; Jeddi-Tehrani M; Lidströmer N; Strigård K; Eriksson E; Samanci A; Choudhury A; Nilsson B; Rossmann ED; Mosolits S; Mellstedt H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2004;53(4):331-337

Functional HLA-DR T cell epitopes of CEA identified in patients with colorectal carcinoma immunized with the recombinant protein CEA.

Ullenhag GJ; Fagerberg J; Strigård K; Frödin J-E; Mellstedt H
Article: RADIOTHERAPY AND ONCOLOGY. 2004;70(2):171-175

Phase I study of UFT plus leucovorin with radiotherapy in patients with inextirpable non-rectal gastrointestinal cancer.

Byström P; Frödin J-E; Berglund A; Wilking N; Glimelius B
Article: ACTA ONCOLOGICA. 2004;43(3):276-279

A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer.

Gyldenkerne N; Glimelius B; Frödin JE; Kjaer M; Pfeiffer P; Hansen F; Keldsen N; Sandberg E; Jakobsen A
Article: INTERNATIONAL JOURNAL OF CANCER. 2003;105(5):717-723

Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A.

Liljefors M; Nilsson B; Hjelm Skog A-L; Ragnhammar P; Mellstedt H; Frödin J-E
Article: CLINICAL CANCER RESEARCH. 2003;9(7):2447-2456

Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response.

Ullenhag GJ; Frödin J-E; Mosolits S; Kiaii S; Hassan M; Bonnet MC; Moingeon P; Mellstedt H; Rabbani H
Article: LAKARTIDNINGEN. 2003;100(26-27):2312-2313

[Palliative chemotherapy in advanced colorectal cancer can often be administered intermittently].

Glimelius B; Berglund A; Frödin J-E; Nygren P
Article: ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY. 2003;112(3):236-241

Decreasing incidence of malignant tumors of the paranasal sinuses in Sweden. An analysis of 141 consecutive cases at Karolinska Hospital from 1960 to 1980.

Norlander T; Frödin J-E; Silfverswärd C; Anggård A
Article: ANTICANCER RESEARCH. 2003;23(2C):1789-1794

5-FU split dose; a phase I/II and pharmacokinetic study of a different schedule of the Nordic regimen in advanced colorectal carcinoma.

Berglund A; Carlsson G; Gustavsson B; Frödin J-E; Ragnhammar P; Glimelius B
Article: ACTA ONCOLOGICA. 2003;42(5-6):416-429

Radiotherapy practices in Sweden compared to the scientific evidence.

Lindholm C; Cavallin-Ståhl E; Ceberg J; Frödin J-E; Littbrand B; Möller TR; SBU Survey Group
Article: ACTA ONCOLOGICA. 2003;42(5-6):387-410

A prospective survey of radiotherapy practice 2001 in Sweden.

Möller TR; Brorsson B; Ceberg J; Frödin J-E; Lindholm C; Nylén U; Perfekt R; SBU Survey Group
Article: ACTA ONCOLOGICA. 2003;42(5-6):357-365

The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001--summary and conclusions.

Ringborg U; Bergqvist D; Brorsson B; Cavallin-Ståhl E; Ceberg J; Einhorn N; Frödin J-E; Järhult J; Lamnevik G; Lindholm C; Littbrand B; Norlund A; Nylén U; Rosén M; Svensson H; Möller TR
Article: ANNALS OF ONCOLOGY. 2002;13(12):1868-1873

Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer.

Glimelius B; Ristamäki R; Kjaer M; Pfeiffer P; Skovsgaard T; Tveit KM; Linné T; Frödin JE; Boussard B; Oulid-Aïssa D; Pyrhönen S
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2002;51(5):255-262

Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression.

Skog A-LH; Wersäll P; Ragnhammar P; Frödin J-E; Mellstedt H
Article: CLINICAL CANCER RESEARCH. 2002;8(6):1772-1778

A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer.

Malmberg K-J; Lenkei R; Petersson M; Ohlum T; Ichihara F; Glimelius B; Frödin J-E; Masucci G; Kiessling R
Article: HYBRIDOMA. 2002;21(2):99-101

MAb17-1A and cytokines for the treatment of patients with colorectal carcinoma.

Frödin J-E; Fagerberg J; Hjelm Skog A-L; Liljefors M; Ragnhammar P; Mellstedt H
Article: CANCER RESEARCH. 2002;62(5):1364-1369

Induction of IgG subclass responses in colorectal carcinoma patients vaccinated with recombinant carcinoembryonic antigen.

Ullenhag GJ; Frödin J-E; Strigård K; Mellstedt H; Magnusson CGM
Article: ACTA ONCOLOGICA. 2002;41(6):525-531

Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer.

Jakobsen A; Berglund A; Glimelius B; Frödin J-E; Hansen F; Kjaer M; Madsen EL; Sandberg E; Poulsen JP; Carlsson G; Gustavsson B; Nordic Gastrointestinal Tumour Therapy Group, Norw
Article: CLINICAL IMMUNOLOGY. 2001;99(1):65-74

Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation.

Ullenhag G; Bird C; Ragnhammar P; Frödin JE; Strigård K; OIsterborg A; Thorpe R; Mellstedt H; Wadhwa M
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 1999;48(8):463-470

Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma.

Hjelm Skog A; Ragnhammar P; Fagerberg J; Frödin J; Goldinger M; Koldestam H; Liljefors M; Nilsson B; Shetye J; Wersäll P; Mellstedt H
Article: CLINICAL CANCER RESEARCH. 1998;4(8):1921-1929

Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor.

Shetye J; Ragnhammar P; Liljefors M; Christensson B; Frödin JE; Biberfeld P; Mellstedt H
Article: ACTA ONCOLOGICA. 1997;36(5):465-469

Multiple primary malignant tumors in a national cancer registry--reliability of reporting.

Frödin JE; Ericsson J; Barlow L
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 1996;42(2):81-87

Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A.

Fagerberg J; Ragnhammar P; Liljefors M; Hjelm AL; Mellstedt H; Frödin JE
Article: ACTA ONCOLOGICA. 1996;35 Suppl 7:70-74

Prostate cancer.

Frödin JE
Article: ACTA ONCOLOGICA. 1996;35 Suppl 7:46-53

Lung cancer.

Frödin JE
Article: ACTA ONCOLOGICA. 1996;35(8):967-979

Radiotherapy in Sweden--a study of present use in relation to the literature and an estimate of future trends.

Frödin JE; Jonsson E; Möller T; Werkö L
Article: CANCER RESEARCH. 1995;55(24):6092-6096

Mutation screening in the hMLH1 gene in Swedish hereditary nonpolyposis colon cancer families.

Tannergård P; Lipford JR; Kolodner R; Frödin JE; Nordenskjöld M; Lindblom A
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 1995;7(5):1049-1056

Different dose regimens of the mouse monoclonal-antibody 17-1a for therapy of patients with metastatic colorectal-carcinoma.

Ragnhammar P; Frodin J; Hjelm A; Fagerberg J; Wersall P; Lindemalm C; Nilsson B; Fox K; Magnusson I; Ewerth S; Thor K; Secher E; Mellstedt H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 1995;40(6):367-375

Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies.

Ragnhammar P; Fagerberg J; Frödin JE; Wersäll P; Hansson LO; Mellstedt H
Article: CANCER BIOTHERAPY. 1995;10(1):5-12

Subcutaneous interleukin-2 and alpha-interferon in advanced colorectal carcinoma. A phase II study.

Hjelm AL; Ragnhammar P; Fagerberg J; Magnusson I; Frodin JE; Svanstrom R; Shetye J; Mellstedt H; Wersall JP
Show more

All other publications

Review: EUROPEAN JOURNAL OF CANCER. 2024;202:114010

Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors.

Helgadottir H; Matikas A; Fernebro J; Frödin J-E; Ekman S; Rodriguez-Wallberg KA
Corrigendum: CLINICAL CANCER RESEARCH. 2019;25(9):2939

Correction: Durable Carcinoembryonic Antigen (CEA)-Specific Humoral and Cellular Immune Responses in Colorectal Carcinoma Patients Vaccinated with Recombinant CEA and Granulocyte/Macrophage Colony-Stimulating Factor.

Ullenhag GJ; Frödin J-E; Jeddi-Tehrani M; Lidströmer N; Strigård K; Eriksson E; Samanci A; Choudhury A; Nilsson B; Rossmann ED; Mosolits S; Mellstedt H
Meeting abstract: ANNALS OF ONCOLOGY. 2018;29:vi31

Molecular treatment stratification in second-line treatment of pancreatic adenocarcinoma: PePaCaKa-001

Kordes M; Lohr M; Malgerud L; Kaduthanam S; Frodin J-E; Karimi M; Yachnin J; Moro CF; Ghazi S; Heuchel R; Wirta V; Huelsewig C; Stecker K; Del Chiaro M; Ostman A; Engstrand L; Brock S; Gustafsson-Liljefors M
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(15):e16243

Palliative treatment of pancreatic adenocarcinoma in a real-world setting.

Kordes M; Malgerud O; Karimi M; Frodin J-E; Liljefors MG; Loehr M
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(15):e16214

Applying evidence-based software for NGS in pancreatic cancer: First results from the PePaCaKa study.

Loehr M; Kordes M; Malgerud L; Kaduthanam S; Frodin JE; Karimi M; Yachnin J; Moro CF; Ghazi S; Heuchel RL; Wirta V; Huelsewig C; Stecker K; Del Chiaro M; Ostman A; Lars E; Brock S; Gustavsson-Liljefors M
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2011;47:S595-S596

Phase I Dose-escalation Study of AXL1717: a Novel Targeted Oral Insulin-like Growth Factor-1 Receptor (IGF-1R) Inhibitor and Its Implications for Patients With Non-small Cell Lung Carcinoma

Ekman S; Harmenberg J; Stahl B; Hedlund A; Bergstrom S; Frodin J; Bergqvist M
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2011;29(15):3526

A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC)

Johnsson A; Frodin J; Berglund A; Hagman H; Sundberg J; Bergstrom D; Christensen RD; Keldsen N; Spindler KG; Jakobsen AKM
Meeting abstract: CANCER RESEARCH. 2011;71:1276

A novel targeted oral insulin-like growth factor 1 (IGF-1) receptor inhibitor and its implications for patients with squamous cell lung carcinoma

Ekman S; Harmenberg J; Hedlund AJ; Bergstrom S; Frodin JE; Bergqvist M
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2010;28(15):e13019

Clinical phase I/II study with the insulin-like growth factor-1 receptor inhibitor AXL1717: Future implications for patients with squamous non-small cell lung carcinoma?

Ekman S; Frodin J; Harmenberg J; Bergman A; Hedlund A; Dahg P; Bergstrom S; Bergqvist M
Letter: ANNALS OF ONCOLOGY. 2010;21(5):1127-1128

Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study.

Glimelius B; Spindler KL; Frödin J-E; Berglund A; Byström P; Qvortrup C; Jakobsen A; Pfeiffer P
Meeting abstract: MOLECULAR CANCER THERAPEUTICS. 2009;8(12):B256

A novel targeted oral insulin-like growth factor 1 (IGF-1) receptor inhibitor in clinical phase I/II testing

Harmenberg J; Ekman S; Bergqvist M; Frodin J-E; Larsson O; Axelson M
Published conference paper: ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. 2000;910:254-261

Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma.

Mellstedt H; Fagerberg J; Frödin JE; Hjelm-Skog AL; Liljefors M; Markovic K; Mosolits S; Ragnhammar P
Review: CURRENT OPINION IN HEMATOLOGY. 1999;6(3):169-175

Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors.

Mellstedt H; Fagerberg J; Frödin JE; Henriksson L; Hjelm-Skoog AL; Liljefors M; Ragnhammar P; Shetye J; Osterborg A
Review: INTERNATIONAL JOURNAL OF CANCER. 1996;:1-72

Mass screening for prostate cancer SBU - The Swedish Council on Technology Assessment in Health Care

Johansson JE; Abrahamsson PA; Adami HO; Adolfsson J; Carlsson P; Damber JE; Gustavsson O; Hallerby N; Landberg T; Marke LA; Norming U; Nyman CR; Ponten J; Rentzhog L; Vang J; Werko L; Jonsson E; Frodin JE; Hermeren G; Svardsudd K; Norlen BJ; Pettersson S; Hoisaeter PA; Gustafson R
Other: CANCER RESEARCH. 1995;55(9):1824-1827

Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes.

Fagerberg J; Hjelm AL; Ragnhammar P; Frödin JE; Wigzell H; Mellstedt H

Employments

Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2023-2026

Degrees and Education

Docent, Karolinska institutet, 1998

Supervisor

Stina Fuentes, Adverse effects and quality of life after radiotherapy and surgery for rectal cancer - a randomized controlled trial enriched with register data, 2016

Articles

All other publications

Employments

Degrees and Education

Supervisor

News from KI

Events from KI